Given that effects of SGLT2i mimics catabolic state such as the increase of fat oxidation, ketone production and glucagon/insulin ratio, the administration of SGLT2i could be expected to enhance catabolic response during night and to restore dysregulated metabolic rhythm in obesity or T2DM patients. The gene discussed is INS; the disease is Obesity.